NCT07024160View on ClinicalTrials.gov

Phase I Study of MT1011 Injection in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Interventions
DRUG

MT1011

MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.

DRUG

Placebo

This intervention contains no active ingredients

Trial Locations (1)

100038

RECRUITING

Beijing Shijitan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY